CDMO– tag –
-
RegMedNet Highlights Specialized Partnerships to Overcome Cell Therapy Challenges: New Strategies for Accelerated Commercialization
RegMedNet Unknown Overview RegMedNet's latest 'Cell Therapy Weekly' edition spotlights emerging specialized partnerships aimed at resolving critical challenges in the cell therapy sector. These collaborations focus on streamlining comple... -
CDMO Capacity Crunch Persists in Cell and Gene Therapy Sector: Strategic Partnerships Crucial for Accelerating Innovation
Contract Pharma USA Overview The cell and gene therapy (CGT) sector faces a severe and persistent capacity crunch among Contract Development and Manufacturing Organizations (CDMOs), driven by soaring demand. This bottleneck significantly... -
Biopharma’s Evolving Blueprint: AGC Biologics Expands Global Capacity, Enzene Drives Continuous Manufacturing Adoption
Pharma Manufacturing USA Overview This news digest highlights several pivotal developments in the biopharmaceutical manufacturing sector, showcasing an industry-wide acceleration towards enhanced capacity and technological innovation. Ke... -
Biomanufacturing Reorients: Geopolitical Forces Drive Sourcing to Qualified, Regional Capacity, with Cellares Pioneering IDMO Smart Factories
Pharma's Almanac USA Overview Geopolitical forces are profoundly reshaping biomanufacturing procurement, driving a surge in demand for 'qualified capacity' – providers with specialized expertise and robust regulatory compliance. This shi... -
AGC Biologics: Job Posting Reveals Broad Biomanufacturing Scope, Spanning Proteins to Gene Therapies
Myworkdayjobs.com USA Overview A recent student assistant job posting from AGC Biologics has inadvertently showcased the company's remarkably extensive Contract Development and Manufacturing Organization (CDMO) capabilities. The company ... -
CDMOs Accelerate GLP-1 Manufacturing, Outpacing Traditional Facility Builds to Meet Soaring Demand
Pharma Advancement USA Overview Contract Development and Manufacturing Organizations (CDMOs) are rapidly scaling their manufacturing capabilities for GLP-1 receptor agonists, providing quicker solutions than ground-up facility constructi... -
July 2026 Pharma M&A Review Highlights Manufacturing Partnerships and AI Innovation as Key Trends, Featuring Major Investments by Lonza, AGC Biologics, and Evonik
Biospectrum Jobs India Overview A July 2026 review of pharmaceutical M&A activities identifies manufacturing partnerships and AI innovation as critical emerging trends. Key players like Lonza expanded biopharmaceutical alliances, AGC... -
Gene Therapy’s Backbone: Oxford Biomedica Acquires ABL Europe, Driving Consolidation in Viral Vector Manufacturing
Industry News UK Overview The viral vector manufacturing market, crucial for gene therapy commercialization, is experiencing accelerated consolidation driven by M&A, exemplified by Oxford Biomedica's acquisition of ABL Europe. This s... -
AGC Biologics Accelerates Cell & Gene Therapy Commercialization with Expanded Viral Vector Manufacturing Platforms
Facebook (AGC Biologics page) USA Overview AGC Biologics is significantly expanding its specialized viral vector manufacturing services for the rapidly growing cell and gene therapy (CGT) sector. The company now offers comprehensive adhe... -
APAC’s Biomanufacturing Ascent: Australia Pioneers Viral Vector Production for Gene Therapies
Industry Publication Australia Overview The Asia-Pacific (APAC) region is rapidly accelerating its specialized manufacturing capabilities for high-value modalities like viral vectors and cell therapies, moving beyond traditional API prod...
